P0603 The real-world use of intravenous and subcutaneous Vedolizumab in IBD across Australia and New Zealand, Crohn’s Colitis Cure Data Insight’s Program
Wen‐Yu Su(Liverpool Hospital), Jane M. Andrews(Health Net), Kate D. Lynch(University of Oxford), Simon Ghaly(UNSW Sydney), Susan J. Connor(Liverpool Hospital), Yoon‐Kyo An(Mater Hospital), Alistair Forbes(University of Otago), Ian C. Lawrance(University of Western Australia), L Brett(Logan Hospital), W.J. Wilson(Commonwealth Scientific and Industrial Research Organisation), Gregor Walker(The University of Queensland), Gabrielle Wark(St Vincent's Hospital Melbourne)
Cited by 0
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
|Nature Genetics|2011|1.4k